Scalper1 News
The FDA said Thursday that it had approved Spectrum Pharmaceuticals’ (SPPI) drug Beleodaq for patients with peripheral T-cell lymphoma (PTCL), sending Spectrum’s stock up as much as 6.3% early Thursday. Spectrum was up more than 1%, near 8.80, in midday trading in the stock market today. PTCL is a rare and aggressive form of non-Hodgkin lymphoma, representing 10% to 15% of all cases, the FDA says. The agency’s statement noted that Beleodaq is the Scalper1 News
Scalper1 News